Vor Biopharma

Contributing Author

Recent Articles by Vor Biopharma

Jan-06	Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference VOR GlobeNewswire
Dec-23	Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors VOR GlobeNewswire
Dec-15	Vor Bio Announces $150 Million Private Placement VOR GlobeNewswire
Nov-13	Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update VOR GlobeNewswire
Nov-10	Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock VOR GlobeNewswire
Nov-10	Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock VOR GlobeNewswire
Nov-08	Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China VOR GlobeNewswire
Nov-07	Vor Bio to Participate in Upcoming Investor Conferences VOR GlobeNewswire
Nov-03	Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer VOR GlobeNewswire
Oct-31	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Oct-29	Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data VOR GlobeNewswire
Oct-22	Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjogren's Disease VOR GlobeNewswire
Oct-17	Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 VOR GlobeNewswire
Oct-16	Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine VOR GlobeNewswire
Oct-14	Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjogren's Disease at ACR 2025 VOR GlobeNewswire
Oct-03	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Sep-29	Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjogren's Disease Clinical Study at ACR Convergence 2025 VOR GlobeNewswire
Sep-23	Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer VOR GlobeNewswire
Sep-17	Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM VOR GlobeNewswire
Sep-12	Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum VOR GlobeNewswire
Sep-02	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel VOR GlobeNewswire
Aug-27	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy VOR GlobeNewswire
Aug-26	Vor Bio to Participate in Upcoming Investor Conferences VOR GlobeNewswire
Aug-18	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Aug-13	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjogren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor VOR GlobeNewswire
Aug-04	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer VOR GlobeNewswire
Jul-21	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors VOR GlobeNewswire
Jul-18	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Jul-17	Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer VOR GlobeNewswire
Jul-10	Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer VOR GlobeNewswire
Jul-01	Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Jun-25	Vor Bio Announces $175 Million Private Placement VOR GlobeNewswire
Jun-25	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset VOR GlobeNewswire
May-08	Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value VOR GlobeNewswire

Vor Biopharma

Recent Articles by Vor Biopharma

Upgrade your FINVIZ experience